VPAC1 overexpression is associated with poor differentiation in colon cancer

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6397-6404

  Liu, Shaohua ^a   Zeng, Yunjie ^b   Li, Yunhua ^a   Guo, Wenying ^a   Liu, Jiali ^a   Ouyang, Nengtai ^c  

^a Laboratory of Surgery Pingxiang Health School   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Colon cancer; EGFR; VIP; VPAC1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ADULT; AGED; ARTICLE; CANCER CELL; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DIFFERENTIATION;

ADULT; CELL DIFFERENTIATION; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA, MESSENGER; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84904982067     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1852-x     Document Type: Article

References (37)

1. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217-8.
2. Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature. 1970;225(5235):863-4.
3. Said SI, Mutt V. Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur J Biochem. 1972;28(2):199-204.
4. Gozes I, Brenneman DE. VIP: molecular biology and neurobiological function. Mol Neurobiol. 1989;3(4):201-36.
5. Varela N, Chorny A, Gonzalez-Rey E, Delgado M. Tuning inflammation with anti-inflammatory neuropeptides. Expert Opin Biol Ther. 2007;7(4):461-78. (Pubitemid 46530624)
6. Waschek JA. VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair. Br J Pharmacol. 2013;169:512-23.
7. Laburthe M, Couvineau A, Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides. 2007;28(9):1631-9. (Pubitemid 47371033)
8. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61(3):283-357.
9. Yadav M, Huang MC, Goetzl EJ. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis. Cell Immunol. 2011;267(2):124-32.
10. Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000;60(11):3105-12. (Pubitemid 30395841)
11. Fernandez-Martinez AB, Carmena MJ, Arenas MI, Bajo AM, Prieto JC, Sanchez-Chapado M. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance. Histol Histopathol. 2012;27(8):1093-101.
12. Jaworski DM. Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) and the PACAP-selective receptor in cultured rat astrocytes, human brain tumors, and in response to acute intracranial injury. Cell Tissue Res. 2000;300(2):219-30. (Pubitemid 30333175)
13. Isobe K, Tatsuno I, Yashiro T, Nanmoku T, Takekoshi K, Kawakami Y, et al. Expression of mRNA for PACAP and its receptors in intra- and extra-adrenal human pheochromocytomas and their relationship to catecholamine synthesis. Regul Pept. 2003;110(3):213-7. (Pubitemid 36165058)
14. Robberecht P, Vertongen P, Velkeniers B, de Neef P, Vergani P, Raftopoulos C, et al. Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomas. J Clin Endocrinol Metab. 1993;77(5):1235-9. (Pubitemid 23345475)
15. Juarranz MG, Bolanos O, Gutierrez-Canas I, Lerner EA, Robberecht P, Carmena MJ, et al. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell Signal. 2001;13(12):887-94. (Pubitemid 33139790)
16. Oka H, Jin L, Reubi JC, Qian X, Scheithauer BW, Fujii K, et al. Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas. Am J Pathol. 1998;153(6):1787-96. (Pubitemid 28550666)
17. Levy A, Gal R, Granoth R, Dreznik Z, Fridkin M, Gozes I. In vitro and in vivo treatment of colon cancer by VIP antagonists. Regul Pept. 2002;109(1-3):127-33. (Pubitemid 35292403)
18. Moody TW, Zia F, Draoui M, Brenneman DE, Fridkin M, Davidson A, et al. Avasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc Natl Acad Sci U S A. 1993;90(10):4345-9. (Pubitemid 23148900)
19. Valdehita A, Carmena MJ, Bajo AM, Prieto JC. RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol Cell Endocrinol. 2012;348(1):241-6.
20. El Zein N, Badran B, Sariban E. VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1. J Leukoc Biol. 2008;83(4):972-81. (Pubitemid 351959878)
21. Valdehita A, Bajo AM, Schally AV, Varga JL, Carmena MJ, Prieto JC. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells. Mol Cell Endocrinol. 2009;302(1):41-8.
22. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 2005;1:2005 0010.
23. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. Nature. 1984;311(5985):483-5. (Pubitemid 14035459)
24. Fahrenkrug J, Hannibal J, Tams J, Georg B. Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab. 2000;20(8):1205-14. (Pubitemid 30636756)
25. Erdling A, Sheykhzade M, Maddahi A, Bari F, Edvinsson L. VIP/PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium. Neuropeptides. 2013;47(2):85-92.
26. Castorina A, Giunta S, Mazzone V, Cardile V, D'Agata V. Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells. Peptides. 2010;31(12):2276-83.
27. Herrera JL, Gonzalez-Rey E, Fernandez-Montesinos R, Quintana FJ, Najmanovich R, Pozo D. Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages. J Cell Mol Med. 2009;13(9B):3209-17.
28. Burian B, Storka A, Marzluf BA, Yen YC, Lambers C, Robibaro B, et al. Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients. Peptides. 2010;31(4):603-8.
29. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 1995;270(24):14255-8.
30. Hori Y, Oda Y, Kiyoshima K, Yamada Y, Nakashima Y, Naito S, et al. Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis. J Pathol. 2007;212(2):218-26. (Pubitemid 46852100)
31. 2+], extracellular regulated kinase 1/2, and secretion in cultured rat conjunctival goblet cells. Invest Ophthalmol Vis Sci. 2013;54(4):2872-84.
32. Sato K. Cellular functions regulated by phosphorylation of EGFR on Tyr845. Int J Mol Sci. 2013;14(6):10761-90.
33. Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, Kang X. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol. 2009;34(1):25-32.
34. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605-12. (Pubitemid 43165918)
35. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1-9. (Pubitemid 351324128)
36. Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer. 2003;97(4):960-8. (Pubitemid 36173146)
37. Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer. 2007;7:156.